Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
232.06
+4.65 (+2.04%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,463,638
Open
228.00
Bid (Size)
228.00 (3)
Ask (Size)
234.90 (1)
Prev. Close
227.41
Today's Range
227.41 - 234.06
52wk Range
220.86 - 319.76
Shares Outstanding
144,000,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
November 28, 2023
Via
Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
November 21, 2023
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
Via
Benzinga
Performance
YTD
-14.88%
-14.88%
1 Month
-2.17%
-2.17%
3 Month
-13.41%
-13.41%
6 Month
-22.31%
-22.31%
1 Year
-20.50%
-20.50%
More News
Read More
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Via
Investor's Business Daily
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today
November 16, 2023
Via
Benzinga
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
November 14, 2023
Via
Benzinga
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
Via
Investor's Business Daily
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
Via
The Motley Fool
These Analysts Revise Their Forecasts On Biogen After Q3 Results
November 09, 2023
Via
Benzinga
Expert Ratings for Biogen
November 09, 2023
Via
Benzinga
Thoughts For Thursday: Staying On Top - Barely
November 09, 2023
Via
Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
November 08, 2023
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides
November 08, 2023
Via
Benzinga
Looking Into Biogen's Recent Short Interest
November 06, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
November 01, 2023
Via
Benzinga
Assessing Biogen's Performance Against Competitors In Biotechnology Industry
October 30, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
November 08, 2023
Via
Benzinga
Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics
November 08, 2023
Via
Talk Markets
US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings
November 08, 2023
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount
November 08, 2023
Via
Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
November 06, 2023
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Biogen Appoints Monish Patolawala to its Board of Directors
November 06, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment
October 26, 2023
Via
Investor's Business Daily
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
October 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
October 25, 2023
Via
Benzinga
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
October 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.